Daily Derm Times: March 3, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Celebrating Women’s History Month with Mindy Haws, MD, and the LIMITLESS Initiative

“It's so exciting to see all these incredible female talents behind me. I want to give back and I want to help them climb on my shoulders and go higher,” Haws said.

Edgar Charles, MD, on Long-term Deucravacitinib Psoriasis Data

BMS’ new 5-year data confirms deucravacitinib’s sustained efficacy and safety in psoriasis. Dermatology Times spoke with Edgar Charles, MD, for insights.

Apogee Therapeutics' APG990 Demonstrates Extended Half-Life and Favorable Tolerability in Interim Phase 1 Data

APG990 showed a 60-day half-life and favorable safety, supporting potential 3-6 month maintenance dosing for atopic dermatitis.

Acne and TikTok: What Do Dermatologists Need to Know?

A new qualitative analysis revealed which type of content on acne is trending on the social media platform and how clinicians should respond.

Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria

Phase 3 trial results presented at AAAAI/WAO 2025 highlight dupilumab's efficacy in reducing itch severity and urticaria activity in CSU patients.

The Environmental Cost of Conferences

Single-use packaging and excess sample distribution contribute to environmental harm, necessitating a shift in industry practices.